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INTRODUCTION
Cytomegalovirus (CMV) belongs to Herpesviridae family, a double-stranded 
DNA virus with an outer coat made of protein and an envelope of lipoprotein.1 
CMV infection is fairly common in general population, which starts off with 
flu-like symptoms or asymptomatic presentation but carries a risk of prolonged 
latency. After the initial phase, the virus has the ability to remain dormant 
in different types of host cells in human organs including the colon. Immu-
nocompromised conditions can lead to viral reactivation, replication, and the 
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Cytomegalovirus (CMV) infection is common in individuals with inflammatory bowel disease 
(IBD) and is responsible for relapse, increased severity, and poor outcome if left untreated. Ganciclovir 
is the mainstay of treatment but data regarding its use, mode of administration, and duration of 
treatment is poorly described. We reviewed the practice of treating CMV colitis with different 
regimes of ganciclovir at a district NHS hospital to compare the clinical outcome.
METHODS
35 patients with IBD and concurrent diagnosis of CMV infection were evaluated. The parameters 
studied were clinical outcome in term of clinical response, length of hospital stay, readmission, or 
colectomy with three different regimes of ganciclovir, in addition to treatment for IBD.
RESULTS
35 patients with IBD (ulcerative colitis = 23, Crohn’s disease = 5, Indeterminate colitis = 7) and 
positive diagnosis of CMV infection were studied. Clinical outcome with two weeks of intrave-
nous (IV) ganciclovir regime was superior than one week of IV ganciclovir and two weeks of oral 
Valganciclovir in term of clinical response on day 15 (95.8% vs 74%, 24.3%, respectively p = 0.45) 
and colectomy rate within 3 months (6.25% vs 27.3%, vs 25%, respectively).  
CONCLUSION
CMV colitis is associated with poor outcome in patient with IBD if left untreated. 2 weeks IV 
ganciclovir was associated with a better outcome than 1 week of IV treatment or oral treatment. 
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complications including severe colitis.2,3 
Inflammatory bowel disease (BD) is an immunocom-
promised condition. Additionally, patients are often 
treated with immunosuppressive medications. Both of 
which put such patients at a higher risk of CMV infection.4,5 
CMV infection is commonly described in patients with 
IBD and is considered to be responsible for the disease 
relapse, increased severity of the disease, and poor outcome 
if left untreated.6,7 Although both Crohn’s disease (CD) 
and ulcerative colitis (UC) have propensity to develop 
CMV infection, it has been shown that the infection is 
more prevalent in UC than CD for reasons not completely 
understood.8 This higher infection rate is noticed in those 
who have a latent CMV infection as the immunocom-
promised state of the patient leads to a higher reactivation 
rates. This is particularly important during the phase of 
disease activation and flare-ups, when these patients 
often become seropositive for CMV.9 The diagnosis of 
CMV infection is usually made by the combination of 
CMV antigenemia assay, detection of inclusion bodies in 
the colonic biopsy specimens, and or immunohistochem-
istry using anti-CMV monoclonal antibodies.10
Due to the severity of CMV infection and its long-term 
complications, there has always been a need for early 
diagnosis and proactive treatment. The treatment has 
various approaches that range from the use of anti-viral 
therapy to the use of CMV immunoglobulins.11,12 Gan-
ciclovir is the mainstay of treatment due to its favorable 
outcome and a remission rate of 67-100%.13,14 Data re-
garding its use, mode of administration, and duration of 
treatment is poorly described in the literature. Foscarnet 
has also been shown of proven efficacy in those patients 
who cannot tolerate ganciclovir or if ganciclovir is con-
traindicated.15 
In this study, we looked at our patient population ret-
rospectively to review the treatment of CMV colitis with 
ganciclovir therapy and the clinical outcome associated 




We conducted a retrospective review of the medical 
records of patients at our institution with a diagnosis of 
IBD who were concurrently tested positive for CMV 
colitis between 1st January 2005 and 1st August 2011.  
Non-systematic strategy was used to test all patients who 
received treatment for CMV colitis with ganciclovir. 
Medical records were also electronically searched for re-
lated details. All the patients included in the analysis had 
provided verbal authorization for medical record review 
for research purposes. 
Inclusion criteria
All patients aged 18 years or above with a diagnosis of 
CD, UC, or indeterminate colitis (IC) who were positive 
for CMV serology, viremia on polymerase chain reaction 
(PCR), and or a positive histology for CMV inclusion 
bodies were included in the study. All patients included 
were treated with ganciclovir. 
Exclusion criteria
This was limited to the absence of underlying diagno-
sis of IBD, concurrent diagnosis of enteric infections and 
or positive faecal test for clostridium difficile infection 
(CDI), diagnosis of CMV in post-surgical specimen, loss 
of follow up, or age less than 18 years.
 
Measures and analyses
Demographic and clinical characteristics were obtained 
from the electronic medical record in those patients who 
met entry criteria. Characteristics included age, sex, 
smoking status, type of IBD, anatomic distribution, du-
ration of disease, previous surgery, prior and concurrent 
treatment for IBD, date of CMV diagnosis, duration and 
mode of treatment with ganciclovir, clinical response as 
recorded in the medical notes, CRP level pre-treatment 
and on days 3rd, 5th, 7th, 10th, and 14th and on one month 
after treatment when available, CMV PCR evaluation 
pre- and post-treatment, detection of clostridium difficile 
toxins (CDT), acute or delayed hypersensitivity reactions, 
autoimmune reaction, and outcome in term of colectomy 
or clinical improvement to be discharged from hospitals. 
Clinical response in term of improvement in the frequency 
of diarrhea, rectal bleeding, and abdominal pain were 
retrospectively determined from the medical records. 
In patients with CD, complete response was defined as 
cessation of diarrhea and abdominal cramping. Partial 
response was defined as a reduction in the amount of diar-
rhea and abdominal cramping. Outcomes not meeting one 
of the above definitions were classified as non-response. 
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In patients with UC, complete response was defined 
as cessation of diarrhea, hematochezia, and abdominal 
cramping whereas partial response was defined as a 
reduction in the amount of diarrhea, hematochezia, and 
abdominal cramping. The results of radiological and/or 
endoscopic imaging were documented where available. 
Symptoms scores of the patients were calculated using 
Harvey Bradshaw Index (HBI) in case of CD and Simple 
Colitis Clinical Activity Index (SCCAI) in case of UC 
and IC using the information from the patients’ notes and 
other clinical records. The treatment regime of ganciclo-
vir used to treat CMV colitis with duration and mode 
of treatment were obtained from the medical notes and 
pharmacy electronic record. A total of 35 patients were 
identified who fulfilled the inclusion criteria as above. 
31 out of the 35 patients were treated with ganciclovir 
with three different regimes and were grouped into three 
categories based on the treatment regime. Group 1: those 
who received 2 weeks of intravenous (IV) ganciclovir 
5mg/kg twice a day, group 2: those who received one 
week IV ganciclovir 5mg/kg twice a day, and group 3: 
those who received two weeks oral valganciclovir 900 
mg twice a day.
Ethics
The study was approved by the local Research and 
Ethics Committee. 
Statistical analysis
Descriptive statistics were used to analyze baseline 
characteristics. Fisher’s exact test, χ2 test, and log-rank 
test for discontinuation were used for statistical analysis 
between the groups. P value of 0.05 was considered as sta-
tistically significant. Statistical analyses were conducted 
using Statistical Analysis Software (SAS).
RESULTS
35 patients with pre-existing diagnosis of IBD (UC = 23, 
CD = 5, IC = 7) were identified with a diagnosis of CMV 
infection between 2005 and 2011. The diagnosis of CMV 
infection was confirmed by detection of inclusion bodies 
in biopsy specimens from the colonic mucosa by either 
hematoxylin and eosin (H&E) staining, or immunohisto-
chemistry (IHC) using anti-CMV monoclonal antibodies. 
In most of the cases, CMV viral status was also confirmed 
by PCR. The age range of the patients was 33-89 years 
(mean = 51, F = 14). All 35 patients were admitted to 
hospital with severe diarrhea. Four out of the 35 patients 
were excluded from the study. One of those excluded 
was admitted with severe diarrhea with initial diagnosis 
of IBD, which was later turned out to be ischemic colitis. 
The other three patients required colectomy within 5 days 
of admission for severe UC, after failing medical treat-
ment with IV steroids and no treatment with ganciclovir. 
The diagnosis of CMV in these three cases was made by 
histological examination of the colectomy specimens. All 
the remaining 31 patients were treated with ganciclovir: 
16 patients (group 1) with 2 weeks of IV ganciclovir 5mg/
kg twice a day, 11 patients (group 2) with one week of 
IV ganciclovir 5mg/kg twice a day, and 4 patients (group 
3) with two weeks of oral valganciclovir 900 mg twice a 
day treatment regime as shown in figure 1. Details of the 
patients’ characteristics and demographics data are shown 
in table 1.
In the colectomy section, three out of six patients with 
UC who had colectomy were excluded from the main 
analysis as they did not receive treatment with ganciclovir 
and the diagnosis of CMV was made later on the histo-
logical specimens.
All patients were on steroids for active IBD prior to 
starting ganciclovir. Eight patients (UC = 5, CD = 3) also 
received anti TNF (tumor necrotic factor) treatment prior 
to commencing on ganciclovir. Clinical response was 
recorded as described above on day 3, 7, 10, 14, and 21 
when available from the clinical records.
As described in figure 2, patients in group 1 (two 
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Fig.1: Graph showing demographic characteristics
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weeks IV ganciclovir regime) were shown to do better 
compared with group 2 and group 3 (1 week of IV gan-
ciclovir and 2 weeks of oral valganciclovir regimes) in 
terms of clinical response on week 2 (93.75% vs 71.4 %, 
25%, respectively, p = 0.867). As shown by the graph 
in figure 3, the clinical response rates on day 3 and 7 
were similar in group 1 and group 2 as determined by 
improvement in symptoms score (64% improvement on 
day 3 and 80% improvement on day 7) as compared with 
group 3 (14% improvement on day 3 and 25% improve-
ment on day 7) but 54.6% of the patients in group 2 (6 
out of 11 patients) had recurrence of symptoms within 4 
weeks of stopping the treatment with IV ganciclovir and 
were re-admitted in hospital or reviewed by the healthcare 
physician requiring escalation of medical treatment in 
Table 1: Patients’ Demographic Data
Patients’ characteristics Group 1 (n = 16) Group 2 (n = 11) Group 3 (n = 4) P value
Age 49.7 ± 11 28.8 ± 12.2 45.0 ± 13.6 0.54
Sex M = 14, F = 2 M = 8, F = 3 M = 3, F = 1 0.400
Type of IBD
UC = 11 UC = 6 UC = 3
0.01CD = 2 CD = 2 CD = 1
IC = 3 IC = 3 IC = 0
Extend of disease
Pancolitis = 4 Pancolitis = 2 Pancolitis = 0
0.52
Left sided = 7 Left sided = 5 Left sided = 2
Proctitis = 2 Proctitis = 2 Proctitis = 1
Colonic CD = 1 Colonic CD = 1 Colonic CD = 0
Ileal = 0 Ileal = 0 Ileal = 0
Ileo-colonic = 2 Ileo-colonic = 1 Ileo-colonic = 1
Duration of disease Mean = 13 yrs. Mean = 11 yrs. Mean = 9 yrs. 0.008
Hospital admission 16 11 4 0.06
Steroids 16 11 4 0.60
Thiopurine 8 5 3 0.54
Antibiotics 4 1 3 0.24
Anti TNF 6 1 1 1.00
5 ASA 12 9 3 0.200
Cyclosporine 3 0 1 1.00
Positive serology 14 9 4 0.001
Previous surgery 5 2 1 0.600
Positive cytopathic changes on HE 13 8 3 0.46
Colectomy
(three patients with UC had colectomy without 
treatment with ganciclovir and were excluded)
1 3 1 0.190
Death 0 1 0 1.00
Transfusion reaction 3 0 1 1.00
Side effect 3 1 1 0.88
UC- ulcerative colitis, CD- Crohn’s disease, IC- Indeterminate colitis, TNF- tumor necrotic factor, ASA- aminosalicylic acid
Fig.2: Graph showing clinical outcome, colectomy rate and length 
of stay (10 days)
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the form of steroids. 33.3% of these patients (two out of 
six patients who had reoccurrence of symptoms) were 
tested for CMV re-infection and the results were negative. 
The remaining patients (four out of six patients) were 
not tested. Three out of these four patients (all with UC) 
deteriorated despite treatment and required colectomy. 
In group-1, 93.75% of the patient achieved complete 
clinical response. 75% of the patients in group 1 (12 out 
of 16) were discharged from the hospital within 2 weeks 
of admission and the other 25% (4) stayed more than 2 
weeks, all were discharged within 3.5 weeks (figure 2). 
Two patients (12.5%) in group 1 were readmitted within 
a month due to recurrence of symptoms, one of these 
responded with escalation of treatment while the other 
continued to deteriorate and required colectomy.
Overall, colectomy rate was higher (100%) in those 
patients who did not receive the treatment with IV ganci-
clovir (all three patients with UC) compared with those 
who did (16%, 4/31, p < 0.01) as shown above in figure 4.
As shown in figure-2, prolonged length of stay as in-
patient in hospital (defined as more than 2 weeks) was 
observed in 25% in group 1, 63.6% in group 2, and 100% 
in group 3, respectively (p = 0.027). Symptoms reoccur-
rence requiring re-admission and or escalation of treat-
ment was lower in group 1 compared with other groups 
(12.5%, 54.5%, and 75%, respectively, p = 0.045). The 
Colectomy rate in all three groups within 3 months are 
described by the graph in figure 2, which were 6.25% in 
group 1, 27.3% in group 2, and 25% in group 3.
Symptoms severity score was recorded from the clini-
cal notes against HBI index in patients with CD and SCCAI 
score in patients with UC and IC as described above. The 
pre-treatment symptoms score was considered as 100% 
and reduction in the symptoms score was recorded on day 
3, 5, and 7 was similar in group 1 and group 2 compared 
with group 3. In group 1 and 2, symptoms score was 
reduced to 50% and 52% on day 3, 40% and 42% on day 
5, and 20% and 24% on day 7 compared with group 3 
(86% on day 3, 75% on day 5, and 72% on day 7). Patients 
in group 1 continued to improve with symptoms score of 
12% on day 10 and 5% on day 15 and 30. While in patients 
in group 2, symptoms were reoccurred after stopping the 
infusion with an increase of 40% in the symptom score on 
day 10 and 52% on day 15. The patients in group 3 con-
tinued to have symptoms despite treatment (53% on day 
10, and 44% on day 15). These results however were not 
statistically significant as shown by the graph in figure-3.
As shown by the graphs in figure 5, CRP response 
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Fig.3: Graph showing clinical response in all three groups mea-
sured by percentage reduction in Harvey Bradshaw Index score 
on days 5, 7, 10, and 15. 
Fig.5: Graph showing CRP response in all three groups measured 
pre-treatment and post treatment up to day 30.
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Fig.4: Graph showing colectomy rate with or without treatment 
with Ganciclovir
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rates on day 3 and 5, were superior in group 1 and 2 com-
pared with group 3 but was non-significant (P = 0.67). 
The CRP response was found to be non-predictive but 
improvement in clinical symptoms on day 3 of treatment 
was found to be associated with better outcome. All the 
patients were tested for enteric infection and CDI via 
faecal analysis (ELISA) and none of the patients were 
positive for either enteric infection or CDT. Eight out of 
31 patients (group-1 = 4, group-2 = 1, group-3 = 3) also 
received antibiotic in the form of metronidazole, cipro-
floxacin, and cefotaxime in the first 3-5 days of admission 
for suspected infection. Two out of these patients were 
on cefotaxime for lower respiratory tract infection dur-
ing hospital stay. One death was recorded but detailed 
clinical note investigation revealed that this was due to 
other co-morbidities (predominantly cardio-respiratory 
complication) and was not directly related to CMV coli-
tis. Acute infusion reactions were defined as an adverse 
event that occurred within 1h after infusion. Delayed hy-
persensitivity reactions were defined as the occurrence 
of myalgias, arthralgias, fever, or rash occurring 1-14 
days after ganciclovir treatment. Three patients in group 
1 and one patient of group 3 experienced mild severity 
of acute transfusion reaction. These were dealt by stopping 
the infusion immediately after the initial symptoms and 
clinical signs of infusion reaction and were treated by 
administering IV steroids 100 mg stat and anti-histamine 
(chlorpheniramine 10 mg IV). The infusion was later 
recommenced at a slower rate with close monitoring of 
the patients. These patients were discharged with clear 
instruction to report to Emergency Department on reoc-
currence of any symptoms of delayed allergy reaction. 
Two patients reported mild delayed type of infusion 
reaction in term of headaches and myalgia, which were 
managed with simple analgesics with full recovery. 
Additionally, three patients in group 1 and one patient 
each from group 2 and 3 reported side effects in term of 
joint pain, sore throat, eye pain, hair fall, and body aches. 
There was patchy documentation about some patient that 
these side effects were dealt with symptomatic treatment 
in the form of analgesia.
DISCUSSION
The morbidities associated with IBD are debilitating 
with poor quality of life, prolonged hospital stay, and 
overall cost of treatment. Although it is widely acceptable 
that the course of disease and prognosis is significantly 
affected by concurrent CMV infection, in the absence of 
dedicated studies, the opinion about the impact of CMV 
infection over the course of IDB remains debatable.16 
While some reviews suggested it to be a bystander in 
patients with IBD with no significant deleterious effect 
on the course of the disease,17 other studies, albeit small, 
showed that CMV colitis could aggravate the course of 
pre-existing IBD, increase its refractoriness to IBD therapy, 
and also increases the frequency of complications leading 
to increased colectomy rate.18,19 It is widely accepted 
that outcome of patients with concurrent CMV infection 
in IBD is different in those who were treated with anti-
viral therapy additional to IBD treatment compared with 
those who did not receive any anti-viral therapy.20,22 For 
example, a study by Mariguela and colleagues reviewed 
a population of patients with UC and found a statisti-
cally significant higher proportion of patients with en-
teric tissue CMV, 57.1% in UC compared with 14.3% 
in patients with colorectal cancer.23 Similarly, Nguyen 
and co-workers 24 concluded that there was more reduc-
tion in the number of colectomies performed for patients 
treated with antiviral agents compared with those who 
did not receive anti-viral therapy. In support of this, 
another study by Roblin and colleagues 25 compared 
the outcome of patients with IBD and CMV infection 
with and without anti-viral treatment. The researchers 
found that early use of antiviral treatment delayed the 
occurrence of resistance to steroids and other immuno-
modulatory therapies. On the other hand, a small study 
by Zeki and others reviewed the outcome of 17 patients 
with UC and concurrent diagnosis of CMV. This study 
(presented in an abstract form) found no difference in 
the colectomy rate in those who were treated for CMV 
infection compared with those who were not.26 In another 
study, Matsuoka and co-workers reviewed the outcome 
of 69 patients with active UC and concurrent diagnosis 
of CMV (n = 48) compared with those who did not have 
CMV infection (n = 21). The outcome in term of rates of 
remission and colectomy were not significantly different 
among the CMV reactivation-positive, -negative, and 
CMV IgG negative groups. Furthermore, CMV disap-
peared without treatment with ganciclovir in most of the 
CMV reactivation-positive patients.27 In our study, three 
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patients with severe UC who failed medical treatment 
with steroids and anti TNF and required colectomy, 
were later found to have CMV inclusion bodies in the 
colectomy specimens. These patients were not tested 
for CMV in the beginning and whether earlier testing 
and treatment for CMV with ganciclovir would have 
made any difference in the outcome is beyond from any 
conclusion. 
CMV reactivation can also occur in immunocom-
petent patients, mostly resulting in a condition similar 
to the primary infection but rarely progress to a serious 
systemic illness. It can also occur in immunocompromised 
patients (elderly, under chemotherapy or immunosup-
pressive treatments, AIDS), in whom it can cause a 
more problematic course with a more serious systemic 
involvement. Several diagnostic modalities such as his-
tology including immunohistochemistry, serology, CMV 
culture, PCR for CMV genome and CMV antigenemia 
have been suggested to confirm CMV infection.28,29,30 
Endoscopic findings are essentially non-discriminatory 
and unable to diagnose the presence of CMV infection 
in patients with IBD.31,32,33 Few small studies however 
have suggested that presence of deep punched out liner 
ulceration may favor the presence of CMV infection in 
addition to active IBD but this has not been supported 
by larger series.34,2 In our study, diagnosis of CMV was 
made by detection of inclusion bodies in biopsy specimens 
from the colonic mucosa using hematoxylin and eosin 
(H&E) staining or immunohistochemistry (IHC) using 
anti-CMV monoclonal antibodies. In most cases, CMV 
viral status was also confirmed by PCR.
Despite the conflicting opinion regarding the treatment 
of CMV infection on the background of IBD, ganci-
clovir has been proposed and traditionally used for the 
treatment both in IV as well as oral form. Although 
there was no conclusive data regarding the use, mode 
of administration, and duration of treatment with gan-
ciclovir in CMV colitis, some small studies have sug-
gested ganciclovir in IV form with a standard dosing 
regimen of 5 mg/kg IV every 12 h for 1-3 weeks with a 
possible switch to oral ganciclovir (1 g/8 h) after clini-
cal improvement for the reminder of the course.17,35 In 
a study, Kim and others focused on IV ganciclovir as 
the antiviral agent most effective in patients with mod-
erate to severe, steroid-refractory ulcerative colitis. In 
some other studies, it was found that the early start of 
antiviral therapy, with discontinuation or tapering of 
immunosuppressive therapy, could improve the prognosis 
particularly in patients with UC than in CD.22 This 
dosing regimen is widely acknowledged as the regimen 
of choice for treating CMV when associated with IBD. 
Our results were also in line with these studies because 
the use of IV ganciclovir has been shown to be more 
beneficial than oral ganciclovir 36 due to its increased 
bioavailability; hence when giving ganciclovir IV one 
can expect an added benefit compared with oral medica-
tion. On the other hand, valganciclovir has been proven 
to be as adequate in CMV infection treatment in patients 
after transplantation as IV ganciclovir, but its efficacy 
regarding CMV colitis on the background of IBD has not 
been studied.37 These findings tend to go in line with the 
results encountered in our study, where patients treated 
with 2 weeks of IV ganciclovir showed more favorable 
outcome regarding hospital discharge, shortened length 
of stay, and low colectomy rate. For example, patients 
who were started on 2 weeks of IV ganciclovir showed 
an overall improvement in clinical outcome as well as an 
overall decrease in colectomy rate and duration of stay in 
the hospital when compared with patients who received 
oral valganciclovir or one week of IV ganciclovir. The 
disease reoccurrence rate was higher in those patients 
who received only one week of IV ganciclovir (54.6% vs 
12.5%) compared with the group who received 2 weeks 
of IV infusion. Colectomy rate was also higher in those 
with recurrence of disease after stopping treatment with 
IV ganciclovir. This reflects the inadequacy of one week 
IV infusion in these patients.  
There was a noted decrease in CRP levels starting 
from day 3 of IV treatment compared with patients 
who were on different medication regimens. Despite 
the decreasing levels, this proved not to be an ad-
equate predictor of a better outcome for our patient 
population. We also had a concern that there would 
be an increased risk of Clostridium difficile infection 
(CDI) but our study proved it to be false as none of 
the patients included in the study was tested positive 
for CDI. It is worth noting that the correlation of CDI 
and CMV colitis has not been adequately studied in 
the literature.
A total of eight patients in the study (four in group 1, 
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one in group 2, and three in group 3) received antibiotic. 
Tree of these patients received antibiotic as prophylaxis 
for pneumocystis carinii pneumonia (PCP) being on 
three type of immunosuppression (anti TNF, thiopurine, 
and steroids), two patients received antibiotic for lower 
respiratory tract infection, two for urinary tract infection, 
and one patient received antibiotic for suspected 
infective colitis initially, which was stopped after 48 
hours on confirmation of clear stool specimen. None 
of these patients received antibiotic for complication of 
colitis such as toxic megacolon or perforation. 
In summary, there is a complexity in the association 
of IBD to CMV, and recently, more and more observations 
are made pointing out that the appropriate use of effective 
antiviral drugs, would more probably regain the sensitivity 
to steroids and immunomodulatory therapies and reduce 
the risk of colectomy with production of favorable out-
come in patients with moderate to severe IBD. There are 
still needs to large randomized trials to emphasize these 
observations.
CONCLUSION
CMV colitis is associated with poor outcome in patient 
with IBD if left untreated. Data regarding mode and 
duration of treatment remain poorly defined. In our 
experience 2 weeks of IV ganciclovir was associated 
with a better outcome. Little or no improvement in the 
clinical condition on day 3 of treatment was associated 
with colectomy. Further data are required to evaluate the 
treatment guidance of this condition.
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